PDF Archive

Easily share your PDF documents with your contacts, on the Web and Social Networks.

Share a file Manage my documents Convert Recover PDF Search Help Contact



Aarkstore Frontier Pharma Alzheimers Disease .pdf


Original filename: Aarkstore - Frontier Pharma Alzheimers Disease.pdf
Title: Slide 1
Author: vina

This PDF 1.5 document has been generated by Microsoft® Office PowerPoint® 2007, and has been sent on pdf-archive.com on 14/05/2015 at 11:59, from IP address 111.119.x.x. The current document download page has been viewed 375 times.
File size: 798 KB (10 pages).
Privacy: public file




Download original PDF file









Document preview


Pharmaceuticals &
Healthcare Market Research
Reports

For More Information Visit : www.aarkstore.com

Summary
Large and Innovative Pipeline

The active Alzheimer’s Disease (AD) pipeline is populated with 583 products, with a
highly diverse range of molecular targets. GBI Research analysis revealed a high
degree of innovation in this indication, with 46% of the pipeline being first-in-class
products, acting on over 40 first-in-class molecular targets. In addition, the pipeline is
characterized by the strong presence of therapies that target multiple components
implicated in the amyloid cascade, several molecular targets of which are known to
trigger familial AD. Given that the currently approved therapies for AD are limited to
acetylcholinesterase inhibitors and glutamate receptor antagonists, the pipeline offers a
broad range of treatment options that may possess disease-modifying properties.
However, evaluation of the Preclinical and clinical evidence for their therapeutic
potential reveals that the novelty of the molecular target is not sufficient to effectively
reduce the rate of AD progression in human patients.

For More Information Visit : www.aarkstore.com

Scope
The report covers and includes - A brief introduction to AD, including symptoms, pathophysiology, and overview of
pharmacotherapy and treatment algorithms
- The changing molecular target landscape between market and pipeline and
particular focal points of innovation in the pipeline
- A comprehensive review of the pipeline for first-in-class therapies, analyzed on the
basis of stage of development, molecule type and molecular target
- Identification and assessment of first-in-class molecular targets with a particular
focus on early-stage programs for which clinical utility has yet to be evaluated, as
well as literature reviews of novel molecular targets
- Assessment of the licensing and co-development deal landscape for AD therapies
and benchmarking of deals involving first-in-class versus non-first-in-class-products

For More Information Visit : www.aarkstore.com

Reasons to buy
The report will assist business development and enable marketing executives to
strategize their product launches, by allowing them to - Understand the focal shifts in molecular targets in the AD pipeline
- Understand the distribution of pipeline programs by phase of development,
molecule type and molecular target
- Access a scientific and clinical analysis of first-in-class developmental programs for
AD, benchmarked against non-first-in-class targets
- Access a list of the first-in-class therapies potentially open to deal-making
opportunities

For More Information Visit : www.aarkstore.com

Table of Content
1.1 List of Tables 3
1.2 List of Figures 3
2 Executive Summary 4
3 The Case for Innovation 6
4 Clinical and Commercial Landscape 11
5 Assessment of Product Pipeline Innovation 21
6 Signaling Network, Genetics and Innovation Alignment 35
7 First-in-Class Target Evaluation 39
8 Deals and Strategic Consolidations 75
9 First-In-Class Molecules not Involved in Licensing or Co-development Deals 86
10 Appendix 89

For More Information Visit : www.aarkstore.com

List of Tables
Table 1: Mini-Mental State Exam, 2005 15
Table 2: Alzheimer’s Disease Assessment Scale, Cognitive Subscale, 1984 16

For More Information Visit : www.aarkstore.com

List Of Figures
Figure 1: Innovation Trends in Product Approvals, 1987–2012 6
Figure 2: Sales Performance of First-in-Class and Non-First-in-Class Product post Marketing
Approval, 2006–2013 8
Figure 3: Sales Performance of Central Nervous System First-in-Class and Non-First-in-Class
Products post Marketing Approval, 2006–2013 8
Figure 4: Alzheimer’s Disease, Global, Developmental Pipeline 22
Figure 5: Alzheimer’s Disease, Global, Established and First-in-Class Pipeline 25
Figure 6: Alzheimer’s Disease, Global, Established Developmental Pipeline Part 1, 2014 27
Figure 7: Alzheimer’s Disease, Global, Established Developmental Pipeline Part 2, 2014 28
Figure 8: Alzheimer’s Disease, Global, Established Developmental Pipeline Part 3, 2014 29
Figure 9: Alzheimer’s Disease, Global, Established Developmental Pipeline Part 4, 2014 30
Figure 10: Alzheimer’s Disease, Global, First-in-Class Developmental Pipeline Part 1, 2014 32

Browse full report Or Sample Request @
http://www.aarkstore.com/pharmaceuticals-healthcare/105777/frontier-pharmaalzheimers-disease-identifying-and-commercializing-first-in-class-innovation

For More Information Visit : www.aarkstore.com

Related Reports










2015 Global Infectious Disease Molecular Diagnostics Market: Country Forecasts, Supplier
Shares, Emerging Technologies, Competitive Landscape
2015 European Infectious Disease Molecular Diagnostics Market: Country Forecasts,
Supplier Shares, Emerging Technologies, Competitive Landscape
2015 France Infectious Disease Molecular Diagnostics Market: Country Forecasts, Supplier
Shares, Emerging Technologies, Competitive Landscape
2015 Germany Infectious Disease Molecular Diagnostics Market: Country Forecasts,
Supplier Shares, Emerging Technologies, Competitive Landscape
Global Healthcare IT Integration Market 2015-2019
Dialysis Catheters Market in the US 2015-2019
Global Immunodiagnostics Market 2015-2019
Pharmaceuticals & Healthcare Market Research Reports

For More Information Visit : www.aarkstore.com

Follow Us
https://www.facebook.com/aarkstoredotcom

https://twitter.com/aarkstore

https://plus.google.com/+Aarkstoredotcom/posts

https://www.linkedin.com/company/aarkstore-enterprise

For More Information Visit : www.aarkstore.com


Related documents


aarkstore frontier pharma alzheimers disease
aarkstore alzheimers disease pipeline review
aarkstore alpha antitrypsin deficiency pipeline review
aarkstore degenerative disc disease pipeline review
aarkstore crohns disease pipeline review h2 2014
global alzheimer s disease drugs market


Related keywords